Cerebral Therapeutics Completes $35 million Series B Financing

logo-tm_CerebralTherapeutics

A Fitzsimons Innovation Company, Cerebral Therapeutics announced today a $35 million Series B financing.

AURORA, Colo., Jan. 7, 2020 /PRNewswire/ — Cerebral Therapeutics, a clinical-stage pharmaceutical company developing innovative treatments for uncontrolled neurological diseases, announced today a $35 million Series B financing led by RA Capital Management, with participation from additional new investor Perceptive Advisors and existing investors Vivo Capital, LLC and Granite Point Capital Management, L.P.  Matthew Hammond, Ph.D. of RA Capital Management, and Weston Nichols, Ph.D. of Perceptive Advisors, will join the Board of Directors.

Read Full Article